Chronic Myelogenous Leukemia
INNOVIVE Pharmaceuticals Announces Interim Phase I Data on INNO-406 for the Treatment of Gleevec-resistant or Intolerant Chronic Myelogenous Leukemia
Published in Blood Weekly, May 3rd, 2007
"The data that we have collected from our ongoing Phase I trial with INNO-406 demonstrate that the compound has clinical activity and is safe and well tolerated at all doses tested thus far," stated Steven Kelly, President and CEO of INNOVIVE Pharmaceuticals. "We believe we are in the therapeutic window for this agent. We will continue our Phase I study to finalize the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-05-03)
More Articles from Blood Weekly
- Anemia
Study produces conflicting findings on the use of anti-anemia drug in cancer patients - Anemia
Data Analyses Outline Efficacy and Safety of MIRCERA for the Treatment of Renal Anemia Associated With Chronic Kidney Disease - B-Cell Lymphoma
Data Presented at AACR Meeting Shows Peregrine's Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies - Cancer
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting - Cord Blood
Cord Blood America Announces Record Revenues; Up 71 Percent in 2006; Gross Profit Highest Ever - Cord Blood
Cryo-Cell International, Inc. Reports First Quarter 2007 Results - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
